"Mitomycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
| Descriptor ID |
D016685
|
| MeSH Number(s) |
D02.806.400.249.350 D03.383.097.500.350 D03.633.100.473.412.249.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mitomycin".
Below are MeSH descriptors whose meaning is more specific than "Mitomycin".
This graph shows the total number of publications written about "Mitomycin" by people in this website by year, and whether "Mitomycin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 0 | 2 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 3 | 0 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2009 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 2 | 3 |
| 2021 | 2 | 1 | 3 |
| 2022 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mitomycin" by people in Profiles.
-
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline. J Clin Oncol. 2025 Feb 10; 43(5):605-615.
-
Ten-Year Outcome of a Randomized Trial: Cytoreduction and HIPEC with Mitomycin C Versus Oxaliplatin for Appendiceal Neoplasm with Peritoneal Dissemination. Ann Surg Oncol. 2025 Feb; 32(2):679-686.
-
Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes. Eur Urol Focus. 2023 11; 9(6):1052-1058.
-
The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma. Urol Oncol. 2023 09; 41(9):387.e1-387.e7.
-
Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease. Eur Urol Focus. 2023 09; 9(5):807-812.
-
Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma. J Urol. 2023 05; 209(5):872-881.
-
Molecular mechanisms regulating wound repair: Evidence for paracrine signaling from corneal epithelial cells to fibroblasts and immune cells following transient epithelial cell treatment with Mitomycin C. Exp Eye Res. 2023 02; 227:109353.
-
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes. Urol Oncol. 2023 03; 41(3):147.e15-147.e21.
-
Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study. BJU Int. 2023 04; 131(4):471-476.
-
Drug instillation in the management of urinary tract urothelial carcinoma. Curr Opin Urol. 2022 09 01; 32(5):531-535.